CryoPort (NASDAQ:CYRX) Shares Gap Up on Analyst Upgrade

CryoPort, Inc. (NASDAQ:CYRX) shares gapped up prior to trading on Tuesday after Guggenheim raised their price target on the stock from $11.00 to $12.00. The stock had previously closed at $10.21, but opened at $11.00. Guggenheim currently has a buy rating on the stock. CryoPort shares last traded at $12.3710, with a volume of 243,974 shares changing hands.

Several other brokerages have also weighed in on CYRX. Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a report on Friday, March 27th. Craig Hallum started coverage on CryoPort in a report on Monday, March 30th. They set a “buy” rating and a $15.00 price objective on the stock. Wall Street Zen lowered CryoPort from a “hold” rating to a “sell” rating in a report on Sunday. BTIG Research lifted their price objective on CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Needham & Company LLC lifted their price objective on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.44.

Insider Activity at CryoPort

In related news, CFO Robert Stefanovich sold 38,700 shares of the business’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $7.76, for a total value of $300,312.00. Following the sale, the chief financial officer owned 255,701 shares of the company’s stock, valued at $1,984,239.76. The trade was a 13.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jerrell Shelton sold 7,918 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the completion of the sale, the chief executive officer directly owned 1,054,501 shares in the company, valued at approximately $8,436,008. This represents a 0.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 59,939 shares of company stock valued at $471,183 in the last 90 days. 10.00% of the stock is owned by corporate insiders.

CryoPort News Summary

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Two brokerages raised ratings/targets today — BTIG bumped its target to $17 (buy) and Needham raised its target to $15 (buy), signaling fresh buy-side conviction and sizable upside vs. the recent share price. Benzinga The Fly
• Positive Sentiment: Q1 revenue of $47.8M topped expectations and grew ~16% year-over-year; management raised FY2026 revenue guidance to $192–$196M, which supports the bullish analyst re-rates. PR Newswire
• Positive Sentiment: Commercial cell & gene therapy (CGT) revenue grew 26% YoY and the company now supports 21 approved CGTs and 766 clinical trials globally — evidence of durable demand in higher-value segments. PR Newswire
• Neutral Sentiment: Full earnings materials (transcript, slide deck) are available for deeper read; investors can use these to vet margin drivers and cadence of CGT revenue. Slide Deck / Press Release Earnings Transcript
• Neutral Sentiment: Company issued revenue guidance but did not provide a clear EPS range in the release, leaving near-term profitability trajectory less certain. PR Newswire
• Negative Sentiment: EPS missed estimates: a $0.23 loss vs. consensus of about a $0.20 loss, and the company remains unprofitable — a reminder that revenue growth hasn’t yet translated into GAAP profitability. Zacks
• Negative Sentiment: Despite the revenue beat, CryoPort still shows a negative return on equity and remains loss-making, which could limit multiple expansion unless profitability improves. MarketBeat

Hedge Funds Weigh In On CryoPort

A number of institutional investors and hedge funds have recently bought and sold shares of CYRX. Mak Capital One LLC acquired a new position in CryoPort in the third quarter worth $7,756,000. UBS Group AG boosted its stake in CryoPort by 112.7% in the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after purchasing an additional 705,649 shares in the last quarter. Millennium Management LLC boosted its stake in CryoPort by 23.8% in the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after purchasing an additional 623,896 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in CryoPort by 283.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock worth $4,970,000 after purchasing an additional 387,440 shares in the last quarter. Finally, First Eagle Investment Management LLC acquired a new position in CryoPort in the fourth quarter worth $2,996,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Price Performance

The company has a market cap of $611.26 million, a price-to-earnings ratio of 9.23 and a beta of 1.75. The business has a 50 day simple moving average of $8.92 and a 200 day simple moving average of $9.32.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $45.45 million during the quarter, compared to analyst estimates of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. As a group, sell-side analysts anticipate that CryoPort, Inc. will post -0.73 earnings per share for the current fiscal year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.